Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia.
Braun TP., Okhovat M., Coblentz C., Carratt SA., Foley A., Schonrock Z., Smith BM., Nevonen K., Davis B., Garcia B., LaTocha D., Weeder BR., Grzadkowski MR., Estabrook JC., Manning HG., Watanabe-Smith K., Jeng S., Smith JL., Leonti AR., Ries RE., McWeeney S., Di Genua C., Drissen R., Nerlov C., Meshinchi S., Carbone L., Druker BJ., Maxson JE.
Acute Myeloid Leukemia (AML) develops due to the acquisition of mutations from multiple functional classes. Here, we demonstrate that activating mutations in the granulocyte colony stimulating factor receptor (CSF3R), cooperate with loss of function mutations in the transcription factor CEBPA to promote acute leukemia development. The interaction between these distinct classes of mutations occurs at the level of myeloid lineage enhancers where mutant CEBPA prevents activation of a subset of differentiation associated enhancers. To confirm this enhancer-dependent mechanism, we demonstrate that CEBPA mutations must occur as the initial event in AML initiation. This improved mechanistic understanding will facilitate therapeutic development targeting the intersection of oncogene cooperativity.